🔎 Trials Near Me

Home › Chronic Pain › NCT05788016

Developing an Opioid Taper Intervention Before Total Joint Arthroplasty

Recruiting

Developing and Testing an Opioid Taper Intervention Before Total Knee Arthroplasty: Phase 2 Intervention Development

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks
* currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months
* have a reliable telephone number for contact
* speaks English

Exclusion Criteria:

* Taking opioid medications that include:

  * Buprenorphine
  * Methadone
  * Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine)
  * Transdermal formations of opioid pain medications (e.g., fentanyl patches)

About the study

The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are:

* Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period?

Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.

What is being tested

Sponsor: University of Alabama at Birmingham · Participants: 45 · Started: Jan 10, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT05788016

Locations in the U.S.

AlabamaUAB Hospital-Highlands, Birmingham

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.